Effective treatment and sobaiovir and daclatasvir in treatment of Hepatitis C
Phase 2
- Conditions
- Chronic viral hepatitis C.Chronic viral hepatitis C
- Registration Number
- IRCT2017052426097N2
- Lead Sponsor
- Research Deputy of Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Persons with thalassemia major, which has a history of hepatitis C are and once in the past but failed treatment with interferon treatment were enrolled if they consent
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of hepatitis C virus. Timepoint: 18/5000 After treatment. Method of measurement: The number of virus by PCR.
- Secondary Outcome Measures
Name Time Method Complications of Treatment. Timepoint: Questionnaires and blood tests. Method of measurement: Blood samples and questionnaires of Complications , per month.